Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017

Shanley Smith, Hande Harmanci, Yvan Hutin, Sarah Hess, Marc Bulterys, Racquel Peck, Bharat Rewari, Antons Mozalevskis, Messeret Shibeshi, Mutale Mumba, Linh-Vi Le, Naoka Ishikawa, Désiré Nolna, Leandro Sereno, Charles Gore, David J Goldberg, Sharon Hutchinson

Table of contents

| Appendix 1 | 2 |
|------------|---|
| | |
| Appendix 2 | 4 |
| | |
| Appendix 3 | 5 |

Appendix 1. Responding Member States with official working estimates on key HBV and HCV monitoring and evaluation indicators in 2017 and set targets on (i) reducing morbidity and mortality and (ii) increasing prevention and treatment activities, by WHO region, income group, and focus country.

Appendix 1.1 Responding Member States with official working estimates on key HBV and HCV monitoring and evaluation indicators in 2017, by WHO region,

income group, and focus country.

| | Prevalence | | Incidence | | Diagnosed | | Treatment Coverage | | Suppression Cure | | Mortality | |
|-----------------------|------------|-------|-----------|-------|-----------|-------|--------------------|-------|------------------|-------|-----------|-------|
| | HBV | HCV | HBV | HCV | HBV | HCV | HBV | HCV | HBV | HCV | HBV | HCV |
| Total Responding | | | | | | | | | | | | |
| Member States | 76 | 69 | 46 | 42 | 25 | 31 | 19 | 30 | 11 | 25 | 32 | 34 |
| N=135 (% of N) | (56%) | (51%) | (34%) | (31%) | (19%) | (23%) | (14%) | (22%) | (8%) | (19%) | (24%) | (25%) |
| WHO region | | | | | | | | | | | | |
| Eastern Mediterranean | 11 | 12 | 9 | 9 | 3 | 5 | 5 | 8 | 4 | 7 | 4 | 5 |
| N=16 (% of N) | (69%) | (75%) | (56%) | (56%) | (19%) | (31%) | (31%) | (50%) | (25%) | (44%) | (25%) | (31%) |
| Western Pacific | 15 | 9 | 7 | 5 | 4 | 4 | 4 | 4 | 2 | 3 | 6 | 6 |
| N=19 (% of N) | (79%) | (47%) | (37%) | (26%) | (21%) | (21%) | (21%) | (21%) | (11%) | (16%) | (32%) | (32%) |
| Americas | 6 | 5 | 4 | 3 | 1 | 2 | 0 | 1 | 0 | 1 | 2 | 1 |
| N=19 (% of N) | (32%) | (26%) | (21%) | (16%) | (5%) | (11%) | (0%) | (5%) | (0%) | (5%) | (11%) | (5%) |
| South-East Asia | 4 | 4 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| N= 8 (% of N) | (50%) | (50%) | (13%) | (0%) | (13%) | (13%) | (0%) | (0%) | (0%) | (0%) | (0%) | (0%) |
| Europe | 30 | 31 | 24 | 25 | 14 | 18 | 9 | 15 | 5 | 13 | 18 | 19 |
| N=46 (% of N) | (65%) | (67%) | (52%) | (54%) | (30%) | (39%) | (20%) | (33%) | (11%) | (28%) | (39%) | (41%) |
| Africa | 10 | 8 | 1 | 0 | 2 | 1 | 1 | 2 | 0 | 1 | 2 | 3 |
| N=27 (% of N) | (37%) | (30%) | (4%) | (0%) | (7%) | (4%) | (4%) | (7%) | (0%) | (4%) | (7%) | (11%) |
| Income category | | | | | | | | | | | | |
| High | 29 | 30 | 21 | 22 | 12 | 16 | 7 | 15 | 5 | 15 | 16 | 17 |
| N=41 (% of N) | (71%) | (73%) | (51%) | (54%) | (30%) | (39%) | (17%) | (37%) | (12%) | (37%) | (39%) | (42%) |
| Upper-middle | 18 | 16 | 12 | 10 | 3 | 4 | 3 | 5 | 1 | 2 | 7 | 7 |
| N=32 (% of N) | (56%) | (50%) | (38%) | (31%) | (9%) | (13%) | (9%) | (16%) | (3%) | (6%) | (22%) | (22%) |
| Lower middle | 19 | 14 | 9 | 7 | 6 | 7 | 7 | 7 | 4 | 6 | 5 | 5 |
| N=35 (% of N) | (54%) | (40%) | (26%) | (20%) | (17%) | (20%) | (20%) | (20%) | (11%) | (17%) | (14%) | (14%) |
| Low | 9 | 8 | 3 | 2 | 4 | 4 | 1 | 2 | 0 | 1 | 3 | 4 |
| N=24 (% of N) | (38%) | (33%) | (13%) | (8%) | (17%) | (17%) | (4%) | (8%) | (0%) | (4%) | (13%) | (17%) |
| n/a | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| N=3 (% of N) | (33%) | (33%) | (33%) | (33%) | (05) | (0%) | (33%) | (33%) | (33%) | (33%) | (33%) | (33%) |

Appendix 1.2 Comparison of responding MS with an official working estimate on mortality attributable to viral hepatitis and responding MS with set targets on reducing morbidity and mortality in 2017.

| Targets for reducing morbidity or mortality | | | | | | | | |
|---------------------------------------------|----------|----------|----------|----------|-------------|----------|--|--|
| | HBV | | HCV | | HBV and HCV | | | |
| | Yes | No | Yes | No | Yes | No | | |
| Set | | | | | | | | |
| N=36 (% of N) | 18 (50%) | 18 (50%) | 20 (56%) | 16 (44%) | 18 (50%) | 16 (44%) | | |
| No | | | | | | | | |
| N=34 (% of N) | 4 (12%) | 30 (885) | 5 (15%) | 29 (85%) | 4 (12%) | 29 (85%) | | |

Appendix 1.3 Comparison of responding MS with an official working estimate on the proportion currently on treatment (HBV) or initiated on treatment (HCV) and responding MS with set targets for increasing prevention and treatment activities in 2017.

| Targets for activities to prevent or treat HBV and/or HCV | Official working estimate on proportion currently on treatment (HBV) or initiated on treatment (HCV) in the last year, among people living with chronic hepatitis infection | | | | | | | | |
|-----------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|----------|----------|-------------|----------|--|--|--|
| | HBV | | HCV | | HBV and HCV | | | | |
| | Yes | No | Yes | No | Yes | No | | | |
| Set | | | | | | | | | |
| N=65 (% of N) | 16 (25%) | 49 (75%) | 25 (39%) | 40 (62%) | 15 (23%) | 39 (60%) | | | |
| No | | | | | | | | | |
| N=21 (% of N | 0 (0%) | 21 (100%) | 1 (5%) | 20 (95%) | 0 (0%) | 20 (95%) | | | |

Appendix 2. Email request for information sent to WHO Members States.

Greetings [insert name],

The World Health Organization in collaboration with Glasgow Caledonian University and the World Hepatitis Alliance are in the process of collecting information on country responses to hepatitis. The aim of this project is to track countries' progress in the uptake of the Global Health Sector Strategy on hepatitis. Key results will be made available for World Hepatitis Day on 28 July 2017 and the global results will be presented at the World Hepatitis Summit in São Paulo in November 2017.

In order to gather this information, a country profile form has been created online and can be viewed in the 6 official UN languages. The form is relatively short, and it can be saved onto a computer before submitting. This gives an opportunity to complete it in multiple sessions and consult with other colleagues if necessary before submitting.

We hope to get responses by the end of March 2017.

We kindly ask that you complete your country profile using the following link:

https://ec.europa.eu/eusurvey/runner/CountryResponseProfileOnHepatitisBandC2016 17

Attached is a picture highlighting certain functions on the country profile page.

Please feel free to contact Shanley Smith at Shanley.Smith@gcu.ac.uk or Hande Harmanci at harmancih@who.int if you have any questions. Thank you and we look forward to your response.

Appendix 3. Instructions for completing online country profile on viral hepatitis sent to WHO Member States.

